US20050084885A1
(en)
*
|
1994-01-18 |
2005-04-21 |
The Scripps Research Institute |
Zinc finger protein derivatives and methods therefor
|
US6140466A
(en)
|
1994-01-18 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger protein derivatives and methods therefor
|
US6140081A
(en)
|
1998-10-16 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger binding domains for GNN
|
US7070934B2
(en)
*
|
1999-01-12 |
2006-07-04 |
Sangamo Biosciences, Inc. |
Ligand-controlled regulation of endogenous gene expression
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
US6599692B1
(en)
*
|
1999-09-14 |
2003-07-29 |
Sangamo Bioscience, Inc. |
Functional genomics using zinc finger proteins
|
US20020164575A1
(en)
*
|
1999-09-14 |
2002-11-07 |
Sangamo Biosciences, Inc., A Delaware Corporation |
Gene identification
|
US7329728B1
(en)
*
|
1999-10-25 |
2008-02-12 |
The Scripps Research Institute |
Ligand activated transcriptional regulator proteins
|
WO2001040798A2
(en)
*
|
1999-12-06 |
2001-06-07 |
Sangamo Biosciences, Inc. |
Methods of using randomized libraries of zinc finger proteins for the identification of gene function
|
US20020061512A1
(en)
*
|
2000-02-18 |
2002-05-23 |
Kim Jin-Soo |
Zinc finger domains and methods of identifying same
|
GB0015090D0
(en)
*
|
2000-06-20 |
2000-08-09 |
Implyx Ltd |
Gene-activating conjugates
|
JP2004537260A
(ja)
*
|
2000-12-07 |
2004-12-16 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
ジンクフィンガータンパク質による血管新生の調節
|
CA2435394C
(en)
*
|
2001-01-22 |
2018-01-09 |
Sangamo Biosciences, Inc. |
Modified zinc finger binding proteins
|
US7067617B2
(en)
*
|
2001-02-21 |
2006-06-27 |
The Scripps Research Institute |
Zinc finger binding domains for nucleotide sequence ANN
|
US20050235369A1
(en)
*
|
2001-03-28 |
2005-10-20 |
Yen Choo |
Gene regulation II
|
US20040224385A1
(en)
*
|
2001-08-20 |
2004-11-11 |
Barbas Carlos F |
Zinc finger binding domains for cnn
|
EP1451297A4
(de)
|
2001-12-07 |
2006-06-28 |
Toolgen Inc |
Phänotyp-screening chimärer proteine
|
US20040259258A1
(en)
*
|
2001-12-07 |
2004-12-23 |
Kim Jin-Soo |
Regulation of prokaryotic gene expression with zinc finger proteins
|
US8106255B2
(en)
|
2002-01-23 |
2012-01-31 |
Dana Carroll |
Targeted chromosomal mutagenasis using zinc finger nucleases
|
WO2004018632A2
(en)
*
|
2002-08-23 |
2004-03-04 |
Sangamo Biosciences, Inc. |
High-throughput screen for modulators of chromatin modifying activity
|
US7361635B2
(en)
|
2002-08-29 |
2008-04-22 |
Sangamo Biosciences, Inc. |
Simultaneous modulation of multiple genes
|
AU2003298574B2
(en)
|
2002-09-05 |
2008-04-24 |
California Institute Of Technology |
Use of chimeric nucleases to stimulate gene targeting
|
WO2004099367A2
(en)
*
|
2002-10-23 |
2004-11-18 |
The General Hospital Corporation |
Methods for producing zinc finger proteins that bind to extended dna target sequences
|
US20060166206A1
(en)
*
|
2002-11-15 |
2006-07-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for analysis of regulatory sequences
|
US20050032186A1
(en)
*
|
2002-12-09 |
2005-02-10 |
Kim Jin-Soo |
Regulatory zinc finger proteins
|
CA2532200C
(en)
*
|
2003-07-31 |
2011-08-16 |
Kao Corporation |
Powder composition for paper manufacturing
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
US20120196370A1
(en)
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
WO2006068742A2
(en)
*
|
2004-11-19 |
2006-06-29 |
Children's Memorial Hospital |
Use of cathepsin inhibitors for reversing or preventing resistance of a cancer cell to a cytotoxic agent
|
WO2007062422A2
(en)
*
|
2005-11-28 |
2007-05-31 |
The Scripps Research Institute |
Zinc finger binding domains for tnn
|
WO2007081647A2
(en)
*
|
2006-01-03 |
2007-07-19 |
The Scripps Research Institute |
Zinc finger domains specifically binding agc
|
US20070178499A1
(en)
*
|
2006-01-06 |
2007-08-02 |
The Scripps Research Institute |
Specific Labeling of Protein with Zinc Finger Tags and Use of Zinc-Finger-Tagged Proteins for Analysis
|
EP1993586A4
(de)
*
|
2006-02-09 |
2009-10-21 |
Sangamo Biosciences Inc |
Verfahren zur behandlung von peripherer arterieller erkrankung mit zinkfingerproteinen
|
JP2009537140A
(ja)
*
|
2006-05-19 |
2009-10-29 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
ジヒドロ葉酸還元酵素の不活性化のための方法及び組成物
|
CA2651494C
(en)
*
|
2006-05-25 |
2015-09-29 |
Sangamo Biosciences, Inc. |
Engineered cleavage half-domains
|
EP2765195A1
(de)
|
2006-05-25 |
2014-08-13 |
Sangamo BioSciences, Inc. |
Verfahren und Zusammensetzungen zur Gendeaktivierung
|
US8148129B2
(en)
*
|
2006-06-30 |
2012-04-03 |
The Regents Of The University Of California |
Generation of potent dominant negative transcriptional inhibitors
|
AU2008275649B2
(en)
|
2007-07-12 |
2013-09-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT 8) gene expression
|
CA2937438C
(en)
*
|
2007-09-27 |
2020-07-07 |
Dow Agrosciences Llc |
Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
|
US11235026B2
(en)
|
2007-09-27 |
2022-02-01 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating PD1
|
CA2700231C
(en)
*
|
2007-09-27 |
2018-09-18 |
Sangamo Biosciences, Inc. |
Rapid in vivo identification of biologically active nucleases
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
AU2008317354B2
(en)
|
2007-10-25 |
2014-04-10 |
Ospedale San Raffaele S.R.L. |
Methods and compositions for targeted integration
|
KR101794638B1
(ko)
|
2008-06-10 |
2017-12-04 |
상가모 테라퓨틱스, 인코포레이티드 |
Bax- 및 bak-결함 세포주들의 제조 방법 및 조성물
|
US8703489B2
(en)
|
2008-08-22 |
2014-04-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
WO2010053518A2
(en)
|
2008-10-29 |
2010-05-14 |
Sangamo Biosciences, Inc. |
Methods and compositions for inactivating glutamine synthetase gene expression
|
EP3156494B8
(de)
|
2008-12-04 |
2018-09-19 |
Sangamo Therapeutics, Inc. |
Genomänderung bei ratten mithilfe von zink-finger-nukleasen
|
US8551945B2
(en)
*
|
2009-02-04 |
2013-10-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating neuropathies
|
JP5932632B2
(ja)
|
2009-03-20 |
2016-06-15 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
改変された亜鉛フィンガータンパク質を使用したcxcr4の修飾
|
CA2756833C
(en)
|
2009-04-09 |
2019-11-19 |
Sangamo Biosciences, Inc. |
Targeted integration into stem cells
|
WO2011016840A2
(en)
|
2009-07-28 |
2011-02-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating trinucleotide repeat disorders
|
MY174390A
(en)
|
2009-10-22 |
2020-04-15 |
Sangamo Biosciences Inc |
Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
GEP20176628B
(en)
*
|
2010-01-22 |
2017-02-27 |
Sangamo Biosciences Inc |
Targeted genomic alteration
|
EP2615106B1
(de)
|
2010-02-08 |
2018-04-25 |
Sangamo Therapeutics, Inc. |
Manipulierte Spaltungs-Halbdomänen
|
CA2788850C
(en)
|
2010-02-09 |
2019-06-25 |
Sangamo Biosciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
US8771985B2
(en)
|
2010-04-26 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Genome editing of a Rosa locus using zinc-finger nucleases
|
KR101974036B1
(ko)
|
2010-05-03 |
2019-04-30 |
상가모 테라퓨틱스, 인코포레이티드 |
아연 핑거 모듈을 연결하기 위한 조성물
|
CA2798988C
(en)
|
2010-05-17 |
2020-03-10 |
Sangamo Biosciences, Inc. |
Tal-effector (tale) dna-binding polypeptides and uses thereof
|
CA2805442C
(en)
|
2010-07-21 |
2020-05-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of an hla locus
|
EP2622090B1
(de)
|
2010-09-27 |
2019-06-19 |
Sangamo Therapeutics, Inc. |
Zusammensetzungen zur hemmung des eindringens von viren in zellen
|
US9175280B2
(en)
|
2010-10-12 |
2015-11-03 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating hemophilia B
|
WO2012094132A1
(en)
|
2011-01-05 |
2012-07-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene correction
|
WO2013012674A1
(en)
|
2011-07-15 |
2013-01-24 |
The General Hospital Corporation |
Methods of transcription activator like effector assembly
|
EP3613852A3
(de)
|
2011-07-22 |
2020-04-22 |
President and Fellows of Harvard College |
Beurteilung und verbesserung einer nukleasespaltungsspezifität
|
EP2737063B1
(de)
|
2011-07-25 |
2016-06-01 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen zur änderung eines zystenfibrose-transmembran-leitungsregulator-gens
|
WO2013044008A2
(en)
|
2011-09-21 |
2013-03-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of transgene expression
|
AU2012328682B2
(en)
|
2011-10-27 |
2017-09-21 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of the HPRT locus
|
CA2854819C
(en)
|
2011-11-16 |
2022-07-19 |
Sangamo Biosciences, Inc. |
Modified dna-binding proteins and uses thereof
|
CA2865011C
(en)
|
2012-02-29 |
2021-06-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
RU2650819C2
(ru)
|
2012-05-07 |
2018-04-17 |
Сангамо Терапьютикс, Инк. |
Способы и композиции для опосредованной нуклеазой направленной интеграции трансгенов
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
BR112014031891A2
(pt)
|
2012-06-19 |
2017-08-01 |
Univ Minnesota |
direcionamento genético nas plantas utilizando vírus de dna
|
US10883119B2
(en)
|
2012-07-11 |
2021-01-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for delivery of biologics
|
HUE051612T2
(hu)
|
2012-07-11 |
2021-03-01 |
Sangamo Therapeutics Inc |
Eljárások és készítmények lizoszomális tárolási betegségek kezelésére
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
CN104704110B
(zh)
|
2012-08-29 |
2018-06-01 |
桑格摩生物科学股份有限公司 |
用于治疗遗传性病状的方法和组合物
|
AU2013312801B2
(en)
|
2012-09-04 |
2018-11-15 |
The Scripps Research Institute |
Chimeric polypeptides having targeted binding specificity
|
UA118090C2
(uk)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
CN105264067B
(zh)
|
2012-09-07 |
2020-11-10 |
美国陶氏益农公司 |
Fad3性能基因座及相应的能够诱导靶向断裂的靶位点特异性结合蛋白
|
UA119135C2
(uk)
|
2012-09-07 |
2019-05-10 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб отримання трансгенної рослини
|
ES2824024T3
(es)
|
2012-10-10 |
2021-05-11 |
Sangamo Therapeutics Inc |
Compuestos modificadores de células T y usos de los mismos
|
EP3789405A1
(de)
|
2012-10-12 |
2021-03-10 |
The General Hospital Corporation |
Transkriptionsaktivator-like-effektor-lysinspezifische demethylase-1 (lsd1)-fusionsproteine
|
AU2013355327A1
(en)
|
2012-12-05 |
2015-06-11 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of metabolic disorders
|
US10272163B2
(en)
|
2012-12-07 |
2019-04-30 |
The Regents Of The University Of California |
Factor VIII mutation repair and tolerance induction
|
AU2014214719B2
(en)
|
2013-02-07 |
2020-02-13 |
The General Hospital Corporation |
Tale transcriptional activators
|
WO2014130706A1
(en)
|
2013-02-20 |
2014-08-28 |
Regeneron Pharmaceuticals, Inc. |
Genetic modification of rats
|
AU2014218621B2
(en)
|
2013-02-25 |
2019-11-07 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
WO2014153470A2
(en)
|
2013-03-21 |
2014-09-25 |
Sangamo Biosciences, Inc. |
Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
|
LT3456831T
(lt)
|
2013-04-16 |
2021-09-10 |
Regeneron Pharmaceuticals, Inc. |
Tikslinis žiurkės genomo modifikavimas
|
WO2014182700A1
(en)
|
2013-05-10 |
2014-11-13 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
CA2910489A1
(en)
|
2013-05-15 |
2014-11-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
EP3008186B1
(de)
*
|
2013-06-14 |
2018-11-28 |
Cellectis |
Verfahren zur nichttransgenen genomänderung bei pflanzen
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
EP3988654A1
(de)
|
2013-08-28 |
2022-04-27 |
Sangamo Therapeutics, Inc. |
Zusammensetzungen zur vernetzung von dna-bindungsdomänen und -spaltungsdomänen
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
CA2926078C
(en)
|
2013-10-17 |
2021-11-16 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
CA2926094C
(en)
|
2013-10-17 |
2024-04-02 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
AU2014341925B2
(en)
|
2013-11-04 |
2017-06-29 |
Corteva Agriscience Llc |
Optimal soybean loci
|
US10093940B2
(en)
|
2013-11-04 |
2018-10-09 |
Dow Agrosciences Llc |
Optimal maize loci
|
MX358066B
(es)
|
2013-11-04 |
2018-08-03 |
Dow Agrosciences Llc |
Óptimos loci de soya.
|
CN107223156A
(zh)
|
2013-11-04 |
2017-09-29 |
美国陶氏益农公司 |
最优玉米座位
|
DK3066201T3
(en)
|
2013-11-07 |
2018-06-06 |
Editas Medicine Inc |
CRISPR-RELATED PROCEDURES AND COMPOSITIONS WITH LEADING GRADES
|
BR112016010175A2
(pt)
|
2013-11-11 |
2017-10-03 |
Sangamo Biosciences Inc |
Repressor genético, seus usos, e composição farmacêutica
|
SI3068881T1
(sl)
|
2013-11-13 |
2019-05-31 |
Children's Medical Center Corporation |
Z nukleazo posredovano uravnavanje izražanja genov
|
ES2813367T3
(es)
|
2013-12-09 |
2021-03-23 |
Sangamo Therapeutics Inc |
Métodos y composiciones para ingeniería genómica
|
ES2700596T3
(es)
|
2013-12-11 |
2019-02-18 |
Regeneron Pharma |
Métodos y composiciones para la modificación dirigida de un genoma
|
WO2015088643A1
(en)
|
2013-12-11 |
2015-06-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a genome
|
US20150166982A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting pi3k point mutations
|
HUE051232T2
(hu)
|
2014-02-03 |
2021-03-01 |
Sangamo Therapeutics Inc |
Béta-talasszémia kezelésére szolgáló eljárások és készítmények
|
US10370680B2
(en)
|
2014-02-24 |
2019-08-06 |
Sangamo Therapeutics, Inc. |
Method of treating factor IX deficiency using nuclease-mediated targeted integration
|
WO2015143046A2
(en)
|
2014-03-18 |
2015-09-24 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
US9522936B2
(en)
|
2014-04-24 |
2016-12-20 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (TALE) proteins
|
BR112016025849A2
(pt)
|
2014-05-08 |
2017-10-17 |
Chdi Foundation Inc |
métodos e composições para o tratamento da doença de huntington
|
US9574211B2
(en)
|
2014-05-13 |
2017-02-21 |
Sangamo Biosciences, Inc. |
Methods and compositions for prevention or treatment of a disease
|
WO2015188065A1
(en)
|
2014-06-05 |
2015-12-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease design
|
ES2784754T3
(es)
|
2014-06-06 |
2020-09-30 |
Regeneron Pharma |
Métodos y composiciones para modificar un locus objetivo
|
SI3354732T1
(sl)
|
2014-06-23 |
2020-07-31 |
Regeneron Pharmaceuticals, Inc. |
Z nukleazo posredovan DNA sklop
|
SI3161128T1
(sl)
|
2014-06-26 |
2019-02-28 |
Regeneron Pharmaceuticals, Inc. |
Postopki in sestavki za ciljano genetsko spremembo in postopki uporabe
|
CN107072183B
(zh)
|
2014-07-14 |
2022-01-04 |
华盛顿州立大学 |
消除种系细胞的nanos敲除
|
MA40253A
(fr)
|
2014-07-15 |
2017-05-24 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
US9816074B2
(en)
|
2014-07-25 |
2017-11-14 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
WO2016014837A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Gene editing for hiv gene therapy
|
US9616090B2
(en)
|
2014-07-30 |
2017-04-11 |
Sangamo Biosciences, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
RS62334B1
(sr)
|
2014-09-16 |
2021-10-29 |
Sangamo Therapeutics Inc |
Postupci i sastavi za inženjering genoma posredovan nukleazom i korekciju kod matičnih ćelija hematopoeze
|
EP3561052A1
(de)
|
2014-10-15 |
2019-10-30 |
Regeneron Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur erzeugung oder instandhaltung von pluripotenten zellen
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
CN107208113A
(zh)
|
2014-12-19 |
2017-09-26 |
瑞泽恩制药公司 |
用于通过单步多重靶向进行靶向遗传修饰的方法和组合物
|
US20180002379A1
(en)
|
2015-01-21 |
2018-01-04 |
Sangamo Therapeutics, Inc. |
Methods and compositions for identification of highly specific nucleases
|
WO2016161446A1
(en)
|
2015-04-03 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
US10808020B2
(en)
|
2015-05-12 |
2020-10-20 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
CN108024544B
(zh)
|
2015-07-13 |
2022-04-29 |
桑格摩生物治疗股份有限公司 |
用于核酸酶介导的基因组工程化的递送方法及组合物
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
JP2018525000A
(ja)
|
2015-08-06 |
2018-09-06 |
ザ・キュレーターズ・オブ・ザ・ユニバーシティ・オブ・ミズーリThe Curators Of The University Of Missouri |
改変cd163遺伝子を有する病原体抵抗性動物
|
US11606940B2
(en)
|
2015-08-07 |
2023-03-21 |
Commonwealth Scientific And Industrial Research Organisation |
Method for producing an animal comprising a germline genetic modification
|
AU2016325613B2
(en)
|
2015-09-23 |
2020-06-25 |
Sangamo Therapeutics, Inc. |
Htt repressors and uses thereof
|
JP7109784B2
(ja)
|
2015-10-23 |
2022-08-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
遺伝子編集のための進化したCas9蛋白質
|
CN108473976B
(zh)
|
2015-10-28 |
2022-07-19 |
桑格摩生物治疗股份有限公司 |
肝特异性构建体、因子viii表达盒及其使用方法
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
AU2016361350B2
(en)
|
2015-11-23 |
2023-04-06 |
Sangamo Therapeutics, Inc. |
Methods and compositions for engineering immunity
|
EP3380616A4
(de)
|
2015-11-24 |
2019-11-06 |
Commonwealth Scientific and Industrial Research Organisation |
Herstellung von viren in vogeleiern
|
CN108603188A
(zh)
|
2015-11-24 |
2018-09-28 |
联邦科学技术研究组织 |
在细胞培养物中产生病毒
|
JP7128741B2
(ja)
|
2015-12-18 |
2022-08-31 |
サンガモ セラピューティクス, インコーポレイテッド |
T細胞受容体の標的化破壊
|
CN108699132B
(zh)
|
2015-12-18 |
2023-08-11 |
桑格摩生物治疗股份有限公司 |
Mhc细胞受体的靶向破坏
|
WO2017123757A1
(en)
|
2016-01-15 |
2017-07-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
CA3011049A1
(en)
|
2016-02-02 |
2017-08-10 |
Sangamo Therapeutics, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
CN117431234A
(zh)
|
2016-05-27 |
2024-01-23 |
阿迪根有限公司 |
用于基因组编辑分子的细胞内递送的肽和纳米颗粒
|
US11124805B2
(en)
|
2016-07-13 |
2021-09-21 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
KR20190041476A
(ko)
|
2016-07-29 |
2019-04-22 |
리제너론 파마슈티칼스 인코포레이티드 |
C-절단된 피브릴린-1의 발현을 유도하는 돌연변이를 포함하는 마우스
|
WO2018027078A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harard College |
Adenosine nucleobase editors and uses thereof
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
MX2019002207A
(es)
|
2016-08-24 |
2019-07-15 |
Sangamo Therapeutics Inc |
Regulacion de la expresion genica usando nucleasas modificadas.
|
SG11201901364VA
(en)
|
2016-08-24 |
2019-03-28 |
Sangamo Therapeutics Inc |
Engineered target specific nucleases
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
AU2017324462B2
(en)
|
2016-09-07 |
2024-03-21 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
WO2018067826A1
(en)
|
2016-10-05 |
2018-04-12 |
Cellular Dynamics International, Inc. |
Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
|
US11896615B2
(en)
|
2016-10-13 |
2024-02-13 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
WO2018071868A1
(en)
|
2016-10-14 |
2018-04-19 |
President And Fellows Of Harvard College |
Aav delivery of nucleobase editors
|
BR112019007210A2
(pt)
|
2016-10-20 |
2019-08-13 |
Sangamo Therapeutics Inc |
métodos e composições para o tratamento da doença de fabry
|
CA3041668A1
(en)
|
2016-10-31 |
2018-05-03 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
IL266862B2
(en)
|
2016-12-01 |
2024-01-01 |
Sangamo Therapeutics Inc |
Tau modulators and methods and preparations for their administration
|
CN110494565A
(zh)
|
2016-12-02 |
2019-11-22 |
朱诺治疗学股份有限公司 |
工程化b细胞及相关组合物和方法
|
EP4276187A3
(de)
|
2016-12-08 |
2024-01-17 |
Case Western Reserve University |
Verfahren und zusammensetzungen zur erhöhung der herstellung von funktionalem myelin
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
MX2019008675A
(es)
|
2017-01-23 |
2019-09-18 |
Regeneron Pharma |
Variantes de hidroxiesteroide 17-beta deshidrogenasa 13 (hsd17b13) y usos de estas.
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
KR20190127797A
(ko)
|
2017-03-10 |
2019-11-13 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
시토신에서 구아닌으로의 염기 편집제
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
WO2018195129A1
(en)
|
2017-04-17 |
2018-10-25 |
University Of Maryland, College Park |
Embryonic cell cultures and methods of using the same
|
CN110799492B
(zh)
|
2017-04-28 |
2023-06-27 |
爱康泰生治疗公司 |
用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
|
WO2018204469A2
(en)
|
2017-05-03 |
2018-11-08 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
MX2020000676A
(es)
|
2017-07-18 |
2021-05-14 |
Csl Behring Gene Therapy Inc |
Composiciones y metodos para tratar beta-hemoglobinopatias.
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
CN111511199A
(zh)
|
2017-08-29 |
2020-08-07 |
科沃施种子欧洲股份两合公司 |
改良蓝色糊粉及其他分离系统
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
CN111163633B
(zh)
|
2017-09-29 |
2022-09-09 |
瑞泽恩制药公司 |
包含人源化ttr基因座的非人类动物及其使用方法
|
CA3082251A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
AU2018364660B2
(en)
|
2017-11-09 |
2022-05-19 |
Sangamo Therapeutics, Inc. |
Genetic modification of cytokine inducible SH2-containing protein (CISH) gene
|
IL276081B2
(en)
|
2018-01-17 |
2023-10-01 |
Vertex Pharma |
Quinoxalinone compounds, preparations, methods and kits for increasing the efficiency of genome editing
|
WO2019143678A1
(en)
|
2018-01-17 |
2019-07-25 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
KR20200109358A
(ko)
|
2018-01-17 |
2020-09-22 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna-pk 억제제
|
KR20200118468A
(ko)
|
2018-02-08 |
2020-10-15 |
상가모 테라퓨틱스, 인코포레이티드 |
조작된 표적 특이적 뉴클레아제
|
WO2019179445A1
(en)
|
2018-03-20 |
2019-09-26 |
Tsinghua University |
Alzheimer's disease animal model and use thereof
|
MX2020010461A
(es)
|
2018-04-05 |
2021-01-15 |
Juno Therapeutics Inc |
Linfocitos t que expresan un receptor recombinante, polinucleotidos y metodos relacionados.
|
EP3775238A1
(de)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
Verfahren zur herstellung von zellen, die einen rekombinanten rezeptor exprimieren, und verwandte zusammensetzungen
|
EP3781587A4
(de)
|
2018-04-18 |
2022-03-30 |
Sangamo Therapeutics, Inc. |
Zinkfingerproteinzusammensetzungen zur modulation von huntingtin (htt)
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
AU2019326408A1
(en)
|
2018-08-23 |
2021-03-11 |
Sangamo Therapeutics, Inc. |
Engineered target specific base editors
|
WO2020051283A1
(en)
|
2018-09-05 |
2020-03-12 |
The Regents Of The University Of California |
Generation of heritably gene-edited plants without tissue culture
|
US20210317430A1
(en)
|
2018-09-18 |
2021-10-14 |
Sangamo Therapeutics, Inc. |
Programmed cell death 1 (pd1) specific nucleases
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
WO2020102659A1
(en)
|
2018-11-15 |
2020-05-22 |
The Broad Institute, Inc. |
G-to-t base editors and uses thereof
|
EP3886869A4
(de)
|
2018-11-28 |
2022-07-06 |
Forty Seven, Inc. |
Genetisch modifizierte ablationsresistente hspcs
|
KR20210105914A
(ko)
|
2018-12-20 |
2021-08-27 |
리제너론 파마슈티칼스 인코포레이티드 |
뉴클레아제-매개 반복부 팽창
|
EP3908568A1
(de)
|
2019-01-11 |
2021-11-17 |
Acuitas Therapeutics, Inc. |
Lipide zur lipidnanopartikelfreisetzung von wirkstoffen
|
AU2019428629A1
(en)
|
2019-02-06 |
2021-01-28 |
Sangamo Therapeutics, Inc. |
Method for the treatment of mucopolysaccharidosis type I
|
WO2020163017A1
(en)
|
2019-02-06 |
2020-08-13 |
Klogenix Llc |
Dna binding proteins and uses thereof
|
WO2020181178A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through thymine alkylation
|
WO2020181195A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenine excision
|
WO2020181193A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenosine methylation
|
WO2020181202A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to t:a base editing through adenine deamination and oxidation
|
WO2020181180A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to c:g base editors and uses thereof
|
MX2021011426A
(es)
|
2019-03-19 |
2022-03-11 |
Broad Inst Inc |
Metodos y composiciones para editar secuencias de nucleótidos.
|
EP3946384A1
(de)
|
2019-04-02 |
2022-02-09 |
Sangamo Therapeutics, Inc. |
Verfahren zur behandlung von beta-thalassämie
|
JP2022527809A
(ja)
|
2019-04-03 |
2022-06-06 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗体コード配列をセーフハーバー遺伝子座に挿入するための方法および組成物
|
SG11202108454RA
(en)
|
2019-04-04 |
2021-09-29 |
Regeneron Pharma |
Non-human animals comprising a humanized coagulation factor 12 locus
|
JP7065260B2
(ja)
|
2019-04-04 |
2022-05-11 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
標的化ベクターへの標的化改変の瘢痕のない導入のための方法
|
US20230165976A1
(en)
|
2019-04-10 |
2023-06-01 |
University Of Utah Research Foundation |
Htra1 modulation for treatment of amd
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
MX2021013223A
(es)
|
2019-05-01 |
2022-02-17 |
Juno Therapeutics Inc |
Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos.
|
AU2020265741A1
(en)
|
2019-05-01 |
2021-11-25 |
Editas Medicine, Inc. |
Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
|
EP3801011A1
(de)
|
2019-06-04 |
2021-04-14 |
Regeneron Pharmaceuticals, Inc. |
Nichtmenschliche tiere mit einem humanisierten ttr-locus mit einer beta-slip-mutation und verfahren zur verwendung
|
CN113939595A
(zh)
|
2019-06-07 |
2022-01-14 |
瑞泽恩制药公司 |
包括人源化白蛋白基因座的非人动物
|
AU2020290509A1
(en)
|
2019-06-14 |
2021-11-11 |
Regeneron Pharmaceuticals, Inc. |
Models of tauopathy
|
EP4007596A1
(de)
|
2019-08-01 |
2022-06-08 |
Sana Biotechnology, Inc. |
Dux4+-exprimierende zellen und ihre verwendungen
|
WO2021030666A1
(en)
|
2019-08-15 |
2021-02-18 |
The Broad Institute, Inc. |
Base editing by transglycosylation
|
AU2020336302A1
(en)
|
2019-08-23 |
2022-03-03 |
Sana Biotechnology, Inc. |
CD24 expressing cells and uses thereof
|
TW202130812A
(zh)
|
2019-11-01 |
2021-08-16 |
美商聖加莫治療股份有限公司 |
用於基因體工程之組合物及方法
|
TW202132565A
(zh)
|
2019-11-01 |
2021-09-01 |
美商聖加莫治療股份有限公司 |
Gin重組酶變異體
|
WO2021092513A1
(en)
|
2019-11-08 |
2021-05-14 |
Regeneron Pharmaceuticals, Inc. |
Crispr and aav strategies for x-linked juvenile retinoschisis therapy
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
WO2021108717A2
(en)
|
2019-11-26 |
2021-06-03 |
The Broad Institute, Inc |
Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
|
WO2021158921A2
(en)
|
2020-02-05 |
2021-08-12 |
The Broad Institute, Inc. |
Adenine base editors and uses thereof
|
US11965161B2
(en)
|
2020-03-04 |
2024-04-23 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for sensitization of tumor cells to immune therapy
|
CA3173096A1
(en)
|
2020-03-25 |
2021-09-30 |
Sonja SCHREPFER |
Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions
|
US20230159913A1
(en)
|
2020-04-28 |
2023-05-25 |
The Broad Institute, Inc. |
Targeted base editing of the ush2a gene
|
CN115715203A
(zh)
|
2020-05-06 |
2023-02-24 |
塞勒克提斯公司 |
对细胞进行基因修饰以递送治疗性蛋白质的方法
|
EP4146812A1
(de)
|
2020-05-06 |
2023-03-15 |
Cellectis S.A. |
Verfahren zur gezielten einführung exogener sequenzen in zelluläre genome
|
IL297761A
(en)
|
2020-05-08 |
2022-12-01 |
Broad Inst Inc |
Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
|
KR20230022868A
(ko)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
|
WO2021236852A1
(en)
|
2020-05-20 |
2021-11-25 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
WO2021260186A1
(en)
|
2020-06-26 |
2021-12-30 |
Juno Therapeutics Gmbh |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
IL300516A
(en)
|
2020-08-13 |
2023-04-01 |
Sana Biotechnology Inc |
Methods for treating susceptible patients with hypoimmunogenic cells, and related methods and compounds
|
EP4204545A2
(de)
|
2020-08-25 |
2023-07-05 |
Kite Pharma, Inc. |
T-zellen mit verbesserter funktionalität
|
WO2022098787A1
(en)
|
2020-11-04 |
2022-05-12 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
EP4243609A1
(de)
|
2020-11-16 |
2023-09-20 |
Pig Improvement Company UK Limited |
Influenza-a-resistente tiere mit bearbeiteten anp32-genen
|
EP4271404A2
(de)
|
2020-12-31 |
2023-11-08 |
Sana Biotechnology, Inc. |
Verfahren und zusammensetzungen zur modulierung der car-t-aktivität
|
KR20230158476A
(ko)
|
2021-02-19 |
2023-11-20 |
빔 테라퓨틱스, 인크. |
유전자 요법을 위한 재조합 광견병 바이러스
|
CA3213080A1
(en)
|
2021-03-23 |
2022-09-29 |
Krit RITTHIPICHAI |
Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
IL308097A
(en)
|
2021-05-27 |
2023-12-01 |
Sana Biotechnology Inc |
Hypoimmunogenic cells that include transgenic HLA-E or HLA-G
|
AU2022309875A1
(en)
|
2021-07-14 |
2024-01-25 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
WO2023019226A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
CA3227108A1
(en)
|
2021-08-11 |
2023-02-16 |
Xiaomeng HU |
Genetically modified primary cells for allogeneic cell therapy
|
CA3227613A1
(en)
|
2021-08-11 |
2023-02-16 |
William Dowdle |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
WO2023023553A2
(en)
*
|
2021-08-17 |
2023-02-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions, systems, and methods for activating and silencing gene expression
|
CA3230629A1
(en)
|
2021-09-08 |
2023-03-16 |
Beam Therapeutics Inc. |
Viral guide rna delivery
|
WO2023069790A1
(en)
|
2021-10-22 |
2023-04-27 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
WO2023105244A1
(en)
|
2021-12-10 |
2023-06-15 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
WO2023122337A1
(en)
|
2021-12-23 |
2023-06-29 |
Sana Biotechnology, Inc. |
Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
|
WO2023129974A1
(en)
|
2021-12-29 |
2023-07-06 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2023154578A1
(en)
|
2022-02-14 |
2023-08-17 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
WO2023220043A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified genome for gene therapy
|
WO2023220035A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus compositions and methods for gene therapy
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
WO2023220040A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified capsid for gene therapy
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024031053A1
(en)
|
2022-08-05 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Aggregation-resistant variants of tdp-43
|
WO2024040083A1
(en)
|
2022-08-16 |
2024-02-22 |
The Broad Institute, Inc. |
Evolved cytosine deaminases and methods of editing dna using same
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|